{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-016989","form_type":"8-K","ticker":"MAIA","cik":"0001878313","company_name":"MAIA Biotechnology, Inc.","filed_at":"2026-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.225705+00:00","generated_at":"2026-05-15T05:51:55.100143+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"MAIA activates first U.S. site for Phase 2 THIO-101 trial in advanced NSCLC","bullets":["First U.S. site activated at Summit Medical Group (NJ); four more U.S. sites planned in 2026.","44 active international sites across Europe/Asia; trial evaluates ateganosine as 3L NSCLC therapy.","$2.3M NIH grant funds third-line evaluation; holds FDA Fast Track designation.","2025 data: eight patients with overall survival beyond 2 years, four over 30 months, one at 33 months.","Approximately 50,000 advanced NSCLC patients in U.S. annually progress to third-line treatment."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-016989","json":"https://secwatch.observer/filing/0001493152-26-016989.json","markdown":"https://secwatch.observer/filing/0001493152-26-016989.md","text":"https://secwatch.observer/filing/0001493152-26-016989.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1878313/000149315226016989/0001493152-26-016989-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1878313/000149315226016989/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:51:55.100143+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}